Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.70, $0.12 better than the analyst estimate of $2.58. Revenue for the quarter came in at $895.9 million versus the consensus estimate of $908.19 million.

GUIDANCE:

Charles River Laboratories sees FY2021 EPS of $10.20-$10.30, versus the consensus of $10.25.

• Revenue growth, reported 19.5% – 20.5

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.